With its domination of the indication- and brand-specific analyses, it should come as no surprise that AstraZeneca led the ...

AstraZeneca's oncology sales jump 18% in second-quarter 2025, fueled by key drugs and new launches like Truqap and Datroway.

AstraZeneca chief is irked by cost of doing business as Eli Lilly raises price of Mounjaro after presidential pressure ...

Britain’s cash-strapped Labour government cannot fold to every corporate lobbying campaign. But it ought to heed Soriot and ...

Despite its potential, incorporating new treatments like T-DXd into a first-line setting faces several barriers, explains Michael Hassett, MD, MPH, chief quality officer at Dana-Farber Cancer ...

Boehringer's Hernexeos is now FDA-approved for patients with HER2-positive NSCLC, bringing it into direct competition with ADC Enhertu.

Antibody-drug conjugates are currently being investigated in more than 260 clinical trials.“It’s going to be the next novel ...

AstraZeneca has built its leading presence in the pharma and biotech industry on patent-protected drugs and a developing pipeline that support a wide moat. The strong replenishment of new drugs ...

AstraZeneca ’s AZN second-quarter 2025 core earnings of $1.09 per American depositary share (ADS) came in line with the Zacks ...

Boehringer Ingelheim GmbH won approval in the U.S. for its drug to treat a challenging form of lung cancer, offering a growth avenue for the privately-held German pharmaceuticals company.

With the end of the pandemic, sales of Pfizer’s PFE COVID products, Comirnaty and Paxlovid, have declined from their peak. However, Pfizer’s non-COVID operational revenues are improving, driven by its ...